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Background: Non-alcoholic fatty liver disease (NAFLD) is defined as a spectrum of conditions ranging from
hepatocellular steatosis to steatohepatitis and fibrosis, progressing to cirrhosis, which occur in the absence of
excessive alcohol use. Several animal models capture aspects of NAFLD but are limited either in their representation
of the disease stages or use for development of therapeutics due to the extended periods of time required to
develop full histological features.
Methods: Here, we report the development of a novel rat model for NAFLD that addresses some of these
limitations. We used a fast food diet (FFD) and a CCl4 micro dose (0.5 ml/kg B.wt) for 8 weeks in Wistar rats.
Serological analyses, gene expression profiling and liver histology studies were conducted to investigate the
development of steatosis, steatohepatitis and fibrosis in the FFD-CCl4 model when compared to the individual
effects of a FFD or a micro dose of CCl4 in rats.
Results: The serum biochemical profile of the FFD-CCl4 model showed an increase in liver injury and fibrosis.
This was also accompanied by a significant increase in liver triglycerides (TG), inflammation and oxidative stress.
Importantly, we observed extensive fibrosis confirmed by: i) increased gene expression of fibrosis markers and,
ii) moderate to severe collagen deposition seen as perisinusoidal and bridging fibrosis using H&E, Trichome and
Sirius Red staining.
Conclusions: In summary, we find that the FFD-CCl4 rat model developed NAFLD histological features including,
steatosis, inflammation and fibrosis in 8 weeks showing promise as a model that can be used to develop NAFLD
therapeutics and liver anti-fibrotics.Background
Non-alcoholic fatty liver disease (NAFLD) is defined by a
spectrum of conditions that occur in the absence of
excessive alcohol use and range from hepatocellular
steatosis to steatohepatitis (NASH) and fibrosis, progressing
to cirrhosis [1,2]. The current prevalence of NAFLD in the
western world is ~20–30% of the population [3,4] and is
expected to increase to >40% by 2030 [5], indicating the
growing risk for individuals leading a sedentary lifestyle on
a high-fat, high-carbohydrate, calorie-rich diet.
Research efforts in NAFLD have been aimed at
understanding disease development, progression and
pathophysiology simultaneously facilitating drug discovery.
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unless otherwise stated.been developed involving genetic and diet manipulation,
treatment with toxins as well as combination models [6-19].
Genetic models of NAFLD include AOX null mice [6,7],
MAT1A null mice [8], liver-specific NRF1 knockouts [9],
liver-specific PTEN knockouts [10] and leptin-deficient
obese mice [11,12], which develop NAFLD due to a
disruption in the antioxidant mechanism, fatty acid
metabolism or triglyceride synthesis/secretion. Diet
modulations leading to NAFLD include the methionine
and choline deficient diet-fed mice [13] and high fat diet
(HFD) mice [14,15] wherein, NAFLD severity varies with
diet composition, duration of feeding, species, strain, and
gender of animals. Well-known chemical-induced models
of NAFLD include carbon tetrachloride (CCl4) and
thioacetamide-treated mice [16,17]. The main advantages
of the well-established CCl4 model include convenience
and establishment of both mouse and rat models withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chheda et al. BMC Gastroenterology 2014, 14:89 Page 2 of 9
http://www.biomedcentral.com/1471-230X/14/89evidence of fibrosis/cirrhosis across routes of CCl4
administration. However, multiple reports have revealed
considerable disadvantages in the intraperitoneal, subcuta-
neous, inhalation and oral routes of CCl4 administration,
including chronic peritonitis, necrosis at injection site with
inconsistent fibrosis, respiratory arrest and higher mortality
with inconsistent fibrosis, respectively [19].
Recently, Charlton et al. reported the development of a
fast food diet mouse model (FFD) of NASH recapitulating
features of the metabolic syndrome and NASH with
progressive fibrosis [20]. The FFD comprised of high
saturated fats, cholesterol and fructose, and mimicked the
metabolic profile in NAFLD including obesity and insulin
resistance, along with features of NASH such as increased
inflammation, fibrosis, ER stress and lipoapoptosis.
The model showed significant physiological similarity
to human NASH but took 24 weeks to develop all
the histological features [20].
Here, we report the development of a novel combination
rat model for NAFLD established by modifying the FFD
[20] and administering a micro dose (0.5 ml/kg bwt) of
CCl4 recapitulating steatosis, steatohepatitis and fibrosis in
an accelerated manner (8 weeks). The serum biochemical
profile of the FFD-CCl4 model showed an increase in liver
injury and fibrosis when compared to FFD alone,
CCl4 alone or the chow diet control animals along
with significant increase in liver TG, inflammation and
oxidative stress in the FFD-CCl4 model. Importantly, gene
expression markers of fibrosis were significantly elevated
in the FFD-CCl4 model when compared to FFD or CCl4
alone or the chow diet control animals, which was further
confirmed by histological staining using H&E as well as
assessment of collagen deposition using Trichome and
Sirius red techniques. In summary, we find that the
FFD-CCl4 rat model, in 8 weeks, developed NAFLD
histological features including, steatosis, inflammation
and fibrosis.
Methods
Compliance with ethical requirements
The study protocol, animal maintenance, and experimental
procedures were approved by the Institutional Animal
Ethics Committee (IAEC) of Connexios Life Sciences. All
institutional and national guidelines for the care and use
of laboratory animals were followed. This article does not
contain any studies with human subjects.
Development of animal model
Ten week old Wistar rats (Charles River Labs, USA)
were used. Animals were housed in groups of three
in polypropylene cages and maintained at 23 ± 1°C at
60 ± 10% humidity and 12 hour cycles of light and
dark with free access to feed and water (ad libitum).
Animals were randomly assigned to four groups, consisting10 animals/group per sex. Group G1 comprised of animals
on chow diet, G2 animals were fed a chow diet and
received a CCl4 micro dose of 0.5 ml/kg B.wt, G3 animals
were fed a FFD alone and G4 animals were fed a FFD and
received a CCl4 micro dose of 0.5 ml/kg B.wt. The FFD
consisted of 2 g cholesterol and 0.5 g cholic acid mixed
with normal chow diet made up to 100 g to increase calorie
content in comparison to the chow diet. Corn oil (5 ml/kg
b.wt) was administered through oral gavage once daily to
all animals in G3 and G4 whereas G1 and G2 animals were
given drinking water. Further, 15 g fructose was mixed in
100 ml drinking water for all G3 and G4 animals. Group
G2 and G4 were administered CCl4 (assay purity: >98%) at
0.5 ml/kg B.wt by oral gavage after dissolving in corn oil
once weekly for the first two weeks and then on alternate
weeks thereafter (i.e., 4th, 6th and 8th week). Food
consumption and body weight were measured weekly for
all animals during the experimental period.
The experimental period was 8 weeks and the last
CCl4 dose was administered 48 h prior to sacrificing the
animals. All animals were fasted overnight and body weight
was measured. Blood was collected from the orbital sinus
under isoflurane anesthesia; serum was separated and
subjected for clinical chemistry studies. Animals were
sacrificed and necropsied, the liver was excised immedi-
ately, weighed and taken to estimate liver triglyceride
(TG), glutathione (GSH) and thiobarbituric acid reactive
substances (TBARS) and gene expression profile using
RT-PCR. The rest was preserved, for histology, in 10%
phosphate-buffered formalin.
Clinical chemistry and biomarker analysis
Serum levels of Aspartate transaminase (AST), Alanine
transaminase (ALT), Alkaline phosphatase (ALP), trigly-
ceride (TG), total bilirubin, Gamma-glutamyl transpepti-
dase (GGT) were measured in automated bio- analyzer
EM360 (Transasia Bio-medicals Ltd) using ERBA
Mannheim kits (Transasia Bio-medicals Ltd, India).
Serum procollagen type III levels were measured as per
manufacturer's instructions using the PIIINP ELISA kit
manufactured by USCN Life Science Inc.
Assessment of liver triglyceride, glutathione and TBARS
100 mg of liver sample was collected in 1 ml PBS
(pH 7.4) and lysed using a tissue lyser (25 Hz for 5 min).
Liver TG was extracted as per Folch’s method. Briefly,
0.3 ml of 10% liver homogenate was extracted in 1.5 ml
of chloroform: methanol (2:1) and the organic layer was
dried in a vacuum dryer. The residue was re-suspended in
absolute isopropyl alcohol and TG levels were esti-
mated using DiaSys Diagnostic Systems GmbH kit.
Levels of total glutathione and TBARS in the liver,
known indicators of oxidative stress, were measured
as described earlier [21,22].
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Real-time PCR was used to evaluate expression of COL1A1,
TIMP1, ACTA2, and TGFβ as markers of liver fibrosis,
TNFa and osteopontin were studied for inflammation and
FABP4 for fatty acid trafficking. All primers were procured
from Integrated DNA Technologies, Germany. Total RNA
was extracted from liver using Trizol (Sigma, St. Louis,
MO, USA) followed by chloroform extraction and isopropyl
alcohol precipitation. cDNA was synthesized by reverse
transcription (ABI, CA, USA) and amplified using
MESA Green PCR Master Mix (Eurogenetic, Belgium).
The Primers sequence for assessment of gene expression
profiles are mentioned in Table 1.
Pathology, staging of fibrosis
Formalin-fixed liver samples were paraffin-embedded,
sectioned at 5 μm and stained using hematoxylin and
eosin (H&E) to examine morphology. Masson’s Trichome
and Sirius Red staining techniques were used to assess
fibrosis. All slides were examined under light microscopy
at low (X10), high (X40) magnification and also at X20.
Histological staging were conducted by modification of
earlier methods [23,24]. Grading and scoring for fatty
change, hepatocellular ballooning and inflammation was
conducted, by a pathologist, Dr. Harish Chandrasekharan,
who carried out blind-fold evaluation to the study, as
described in (Additional file 1: Table S1 and Additional
file 2: Table S2).
Statistics
Data are presented as mean ± SEM. Comparisons among
groups were performed with one-way ANOVA followed
















Reverse-TTCCACGCCCAGTTTGAAGGAsignificant differences between groups, p < 0.05 was
considered significant.
Results
Animals on FFD with a micro dose of CCl4 (0.5 ml/Kg B.
wt, po) showed liver injury and fibrosis in 8 weeks
Livers from all animals on FFD with/without CCl4
appeared pale, enlarged and showed a significant increase
in liver weight (p < 0.001) (Table 2). There were no
changes in liver weight and gross morphology in animals
that were administered CCl4 on chow diet. Across all
groups, animals did not show any signs of toxicity or
overt behavioral changes. All animals on the FFD
with/ without CCl4 animals gained >10% weight compared
to the chow diet-fed animals without any change in
weekly food consumption (Additional file 3: Table S3 and
Additional file 4: Table S4).
To estimate liver injury, we compared the serum bio-
chemical profiles of the FFD-CCl4 animals to the FFD,
CCl4 and chow diet controls. ALT, AST, GGT and ALP
(known serum markers of liver injury) and procollagen
type III (known serum marker of fibrosis) were significantly
elevated in the FFD-CCl4 animals compared to the chow
diet controls (Table 3). Serum triglyceride levels were re-
duced significantly in FFD with/ without CCl4. Apart from
the increase in serum triglycerides, animals on a chow diet
administered a CCl4 micro dose did not show a significant
change in the serum biochemical profile when com-
pared to the chow diet controls. However, we did not
observe any changes in blood glucose levels under
both fasting and fed condition across all the groups
(data not shown). Taken together, these data indicate
that the FFD-CCL4 rats show an increase in markers
of liver injury and fibrosis.
In agreement with the liver injury reflected in the serum
biochemical profile, liver TG content was significantly
elevated in FFD and FFD-CCl4 animals (Table 2). Reactive
oxygen species (ROS)-mediated oxidative stress markers
were measured to access liver damage. We observed a
significant (p < 0.01) depletion in liver glutathione levels in
FFD-CCL4 animals compared to FFD and chow diet
controls. In line with this, liver TBARS was elevated in both
FFD and FFD-CCl4 animals (Table 2). Animals on the chow
diet did not show a significant change in oxidative stress
markers with/without CCl4. Thus, along with an increase in
liver injury, the FFD-CCl4 animals also showed an overall
increase in liver steatosis and oxidative stress.
Pro-fibrotic and pro-inflammatory pathways are activated
in the FFD-CCl4 animals
To follow up on elevated liver injury and fibrosis
markers observed in the FFD-CCl4 sera, we studied gene
expression of key genes in inflammation, fibrosis and
fatty acid trafficking known to be involved in NAFLD.
Table 2 Effect on liver oxidative stress markers and liver triglyceride levels
Parameters Chow diet control 0.5 ml/Kg B.wt CCl4 FFD FFD + 0.5 ml/kg B.wt CCl4
Liver TG (mg/g tissue) 6.32 ± 0.79 8.73 ± 1.27 17.17 ± 0.96*** 15.49 ± 1.51***
Liver GSH (μg/mg protein) 7.36 ± 0.62 6.81 ± 0.42 6.95 ± 0.45 2.58 ± 1.10**
Liver TBARS (μM/mg protein) 0.56 ± 0.06 0.60 ± 0.064 3.73 ± 0.67*** 2.10 ± 0.29**
Relative Liver weight (g) 2.49 ± 0.04 2.86 ± 0.08 4.77 ± 0.15*** 4.85 ± 0.16***
Data are expressed as mean ± SEM. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparison post test, **p < 0.01
and ***p < 0.001.
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with fatty acid uptake, transport and metabolism, impli-
cated in development of NASH) were significantly
increased in the FFD-CCl4 animals compared to the
FFD, CCl4 and chow diet controls (Table 2). Similarly,
osteopontin, a marker for immune cell activation was
significantly increased in the FFD and FFD-CCl4 animals
compared to the control animals. In agreement with
this, TGFβ, a well-established marker of fibrosis and
inflammation, was expressed at significantly higher levels
in FFD-CCl4 animals compared to the FFD, CCl4 and
chow diet controls. Other markers of extracellular
matrix (ECM) deposition including COL1A1 and TIMP1
also showed a significant increase in the FFD-CCl4 ani-
mals compared to the FFD and chow diet controls
(Table 4). ACTA2 (ECM deposition marker smooth
muscle actin) did not show significant gene expression
changes in FFD, CCl4 or the FFD-CCl4 animals (Table 4).
TNFα (proinflammatory cytokine implicated in fibrogenesis)
increased both in the FFD and FFD-CCl4 animals.
Animals that were administered a CCl4 micro dose
on the chow diet did not show a significant change
in the expression of key genes in inflammation, fibrosis
and fatty acid trafficking when compared to the chow
diet controls. Similarly, except for the increase in
TNFα, the FFD animals also did not show a change
in the gene expression profile when compared to the
chow diet controls.
Together, these data show that the FFD-CCl4 animals
show pro-fibrotic and pro-inflammatory changes in
gene expression which are not shown by FFD or the
CCl4-treated animals.Table 3 Serum biochemical profile
Parameters Chow diet control 0.5 ml/Kg
AST (IU/L) 118.0 ± 6.93 126.3
ALT (IU/L) 54.92 ± 1.25 59.17
ALP (IU/L) 87.67 ± 6.86 102.4
GGT (IUL) 0.09 ± 0.04 0.06 ±
Procollagen type III (ng/ml) 5.61 ± 0.61 5.65 ±
Triglycerides (mg/dL) 145.3 ± 14.28 96.72 ±
Effect on serum clinical chemistry markers; data are expressed as mean ± SEM. Stati
Dunnett’s multiple comparison post test, *p < 0.05, **p < 0.01 and ***p < 0.001.The FFD-CCl4 mice show an increase in steatosis,
hepatocellular ballooning and fibrosis
Histological examination of liver sections from FFD-CCl4
animals showed a statistically significant increase in
micro vesicular and macro vesicular steatosis, hepatocellu-
lar ballooning and fibrosis compared to the FFD, CCl4
and chow diet controls (Table 5 and Figure 1). As per
the scoring system shown in (Additional file 2: Table S2),
we observed moderate infiltration of mononuclear
inflammatory cells with predominance of macrophages
in both the FFD and FFD-CCl4 animals along with both
periportal and perivenular steatosis and hepatocellular
ballooning which are features of steatohepatitis (Figure 2).
To evaluate collagen distribution, Masson trichome
and picrosirius red staining were carried out (Table 5
and Figure 1). However, liver sections from FFD and
FFD-CCl4 animals showed increased collagen depos-
ition with the latter showing moderate-severe collagen
deposition detectable as perisinusoidal fibrosis and
bridging fibrosis (Figure 1). Importantly, this was true
for all the animals on the FFD-CCl4 regime. Animals
on a chow diet with/without CCl4 did not show a sig-
nificant increase in macro vesicular steatosis, hepato-
cellular ballooning and infiltration of inflammatory
cells (Figure 2).
Hepatocellular ballooning, which has been challen-
ging to establish in animal models of NAFLD, was
observed in the FFD-CCl4 and the FFD animals but
not the CCl4-treated animals (Figure 2). Together
these data indicate that the FFD-CCL4 model recapitulates
the steatosis, inflammatory and fibrotic lesions associated
with NAFLD.B.wt CCl4 FFD only FFD + 0.5 ml/kg B.wt CCl4
± 2.85 138.4 ± 6.91* 146.7 ± 6.91**
± 0.95 62.73 ± 7.72 69.60 ± 4.15*
± 7.44 228.8 ± 38.44*** 227.8 ± 31.62***
0.06 0.00 ± 0.00 3.30 ± 1.17***
0.65 8.29 ± 0.58 14.96 ± 2.19***
8.54* 77.17 ± 7.90** 75.43 ± 4.30**
stical significance was determined using one-way ANOVA followed by
Table 4 Gene expression profiles for Fibrosis, inflammation and fatty acid trafficking
Gene Gene expression profile
Chow diet 0.5 ml/Kg B.wt CCl4 FFD FFD + 0.5 ml/kg B.wt CCl4
Fibrosis
TGFβ1 1.02 ± 0.09 1.00 ± 0.05 1.22 ± 0.17 1.69 ± 0.14*
COL1A1 1.08 ± 0.17 1.56 ± 0.21 2.25 ± 0.32 13.05 ± 1.88***
TIMP1 1.00 ± 0.05 0.81 ± 0.04 1.74 ± 0.15 2.41 ± 0.42**
ACTA2 1.08 ± 0.08 1.00 ± 0.05 1.01 ± 0.12 0.87 ± 0.12
Inflammation
TNFα 1.05 ± 0.13 0.62 ± 0.04 3.59 ± 0.75** 1.30 ± 0.23*
Osetopontin 1.10 ± 0.34 0.86 ± 0.21 5.43 ± 1.14 9.79 ± 2.43**
Fatty acid trafficking
FABP4 1.05 ± 0.15 1.59 ± 0.28 5.63 ± 0.57 45.46 ± 8.64***
Gene expression TGFB1, COlA1, TIMP1, Acta2, TNFa, FABP4 levels in liver; all data are expressed as mean ± SEM. The data measured by quantitative real-time
RT-PCR was statistically analyzed for significant using one-way ANOVA followed by Dunnett’s multiple comparison post test, *p < 0.05, **p < 0.01 and ***p < 0.001.
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NAFLD is a spectrum of disorders ranging from fatty
liver (steatosis), NASH and fibrosis resulting in cirrhosis
[25,26]. Several animal models have been developed to
study NAFLD pathogenesis and screen for therapeutics.
These animal models vary by way of nature of pathology
and evolution of fibrosis [6-19]. Animal models commonly
used to study NAFLD include the high fat diet-induced,
FFD mouse and CCl4-induced liver injury models
[16,17,27-29]. The FFD mouse model develops features of
human NAFLD. However, it takes about 6 months to
establish histological features [20]. Acute/ chronic exposure
to CCl4 has shown elevated serum liver enzymes, steatosis,
centrilobular necrosis, increased liver weight and fibrosis/
cirrhosis. However the CCL4-induced fibrosis model is very
severe and associated with peritonitis, necrosis and
lack of consistent development of fibrosis [19]. Chronic
CCl4 treatment (>2 weeks), on the other hand, is known
to invoke adaptive mechanisms, reducing vulnerability
to oxidative stress and hepatocellular damage with
restorative macrophages showing potential to reverse
fibrosis upon CCl4 withdrawal [28,30,31].
In the current study, we present a rat model of
NAFLD developed over 8 weeks on a modified FFD with
a CCL4 micro dose (0.5 ml CCl4/kg bwt) that capturesTable 5 Scores of liver from chow diet, FFD and FFD-CCl4
Histological scores Chow diet control 0.5 ml/Kg
Fibrosis 00 ± 00 00
Steatosis – micro vesicular 0.33 ± 0.14 0.75
Steatosis – macro vesicular 00 ± 00 00
Hepatocellular ballooning 00 ± 00 0.25
Inflammation 0.75 ± 0.22 1.00
All data are expressed as mean ± SEM. The data was statistically analyzed for signifi
test, **p < 0.01 and ***p < 0.001.steatosis, inflammation and fibrosis stages of NAFLD.
We used CCl4 micro dosing to induce oxidative stress
and inflammation without causing overt hepatotoxic
effects. In course of our studies, we had tested a micro
dose of 1 ml/kg bwt CCl4 (unpublished data). However,
this resulted in mortality leading us to reduce the dose
to 0.5 ml/kg bwt. In this study, we modified the published
FFD composition [20] by increasing the amount of
fructose used in drinking water to mimic a metabolic
overload [32-34] and accelerate disease progression. As
expected, all FFD-CCl4 animals showed an increase in
liver injury, fibrosis and oxidative stress confirmed by
changes in serum AST, ALT, GGT, ALP; Procollagen III,
and liver GSH and TBARS [35-37], respectively. This was
consistent with previous models of CCl4-induced fibrosis
and the FFD mouse model [20,31,38,39].
Serum triglyceride levels were reduced significantly in
FFD with/ without CCl4. This decrease is a distinctive
feature of CCl4 which rapidly increases the triglyceride
accumulation in the liver due to a failure in their
secretory mechanisms [31,39] and also increased uptake
of triglycerides into the liver. We observed, in 8 weeks, an
increase in liver TG, fatty acid trafficking, inflammation
and fibrosis, which was in consistence with earlier
findings where the increase in gene expression of FABP4B.wt CCl4 FFD FFD + 0.5 ml/kg B.wt CCl4
± 00 0.92 ± 0.12*** 2.30 ± 0.21***
± 0.13 2.00 ± 0.21*** 2.60 ± 0.16***
± 00 1.92 ± 0.19*** 2.50 ± 0.17***
± 0.13 1.00 ± 0.17*** 1.50 ± 0.17***
± 0.25 1.75 ± 0.22** 2.00 ± 0.26**
cant using one-way ANOVA followed by Dunnett’s multiple comparison post
Figure 1 Hematoxylin-Eosin (H&E, 1st and 2nd rows), Masson’s trichrome (3rd and 4th rows) and Sirius red (5th and 6th rows) – stained
sections of liver tissues from chow diet, chow diet + 0.5 ml/Kg B.wt CCl4, fast food diet (FFD), FFD + 0.5 ml/Kg B.wt CCl4 fed animals on
8th week. There was no steatosis, hepatocellular ballooning or fibrosis in animals fed with chow diet. Mild micro-vesicular fatty changes and mild
hepatocellular ballooning, without fibrosis observed in animals fed with chow diet + 0.5 ml/Kg B.wt CCl4. Fast food fed animals without CCl4 showing
moderate micro-vesicular and macro-vesicular fatty changes, hepatocellular ballooning and minimal perisinusoidal fibrosis. FFD + 0.5 ml/Kg B.wt CCl4
fed animals showing severe micro-vesicular and macro-vesicular fatty changes with significant hepatocellular ballooning and prominent perisinusoidal,
pericellular region with extensive distribution and bridging fibrosis. All liver sections were evaluated at X10 (low-magnification) and
X40 (high-magnification).
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Figure 2 Row1: Hematoxylin-Eosin (H&E) stained sections of liver tissues from chow diet, chow diet + 0.5 ml/Kg B.wt CCl4, fast food diet
(FFD), FFD + 0.5 ml/Kg B.wt CCl4 fed animals on 8th week. Liver section showing moderate infiltration of inflammatory cells (shown by black
arrows) in fast food fed animals with and without CCl4 along with moderate micro-vesicular and macro-vesicular fatty changes and hepatocellular
ballooning. Mild inflammation was observed in animals fed with chow diet + 0.5 ml/Kg B.wt CCl4. Row2: Hematoxylin-Eosin (H&E) stained sections
of liver tissues. Liver sections showing increased hepatocellular ballooning in fast food fed animals with and without CCl4 along with moderate
micro-vesicular and macro-vesicular fatty changes. All liver sections are represented at X40 (high-magnification).
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inflammation), COL1A1 and TIMP1 (markers of fibrosis)
[40,41], which have been reported and duration for
appearance of liver fibrosis was 24 weeks. In the current
study, the liver histological lesions showed all the fea-
tures of NAFLD in animals treated with FFD-CCl4.
Development of steatosis is largely due to increased
rate of import or synthesis of fatty acids by hepatocytes
that exceeds the rate of export or catabolism [42-44].
Steatosis thus developed has an inflammatory response
which may be precipitated by a variety of stimuli such as
oxidative stress and pro-inflammatory cytokine mediated
hepatocyte injury progressing to NASH [43-46].
Considering how this model is distinct from previous
models of NAFLD is important and we find that the
FFD-CCl4 rat model recreates in 8 weeks most histological
lesions seen in the FFD mouse [20,47,48] with the excep-
tion of a change in serum glycemic/lipid profiles. This
model has not shown features of metabolic syndrome thus
this model does not exactly mimic human NAFLD. The
FFD mouse established by Charlton et al. [20], showed
features of metabolic syndrome with hepatocellular
ballooning and progressive fibrosis which makes it a good
model that mimics human NAFLD but it takes more than
6 months. In the FFD-CCl4 model, although we were
unable to detect insulin resistance or hyprinsulinemia, we
observed steatosis, inflammation and fibrosis associated
with NAFLD in 8 weeks.
A significant aspect of this model is that it is able to
replicate hepatocellular ballooning and fibrosis in 8 weeks.
Developing a rapid fibrosis model in short duration requirea variety of stimuli, thus animals fed a high-fat diet for
more than 24 weeks are associated with their susceptibility
to diet-induced obesity that develop steatohepatitis. In the
current model, FFD along with micro dose CCl4 provoke
an array of responses that results in hepatocellular balloon-
ing, inflammation, and fibrosis. Hepatocellular ballooning
has been difficult to establish but was shown recently in
the FFD mouse by Charlton et al. [20]. In our study,
Masson trichome and picrosirius red staining techniques
revealed increased collagen deposition in the form of
pericellular and bridging fibrosis. The necroinflammatory
foci showed mononuclear infiltration with predominance
of macrophages. Further, expression levels of pro-fibrotic
and pro-inflammatory gene, TGFβ1 increased along
with COL1A1 mRNA levels. Curiously, ACTA2 (ECM
deposition marker smooth muscle actin) did not show
significant gene expression changes in FFD, CCl4 or the
FFD-CCl4 animals and needs to be further assessed for
changes in protein expression.
Interestingly, during model development, we observed
a gender bias for NAFLD development with females being
more susceptible than males. Further studies will be re-
quired to understand the mechanistic reasons for this sus-
ceptibility seen in females and also to precisely understand
the rate of progression of NAFLD in this model. For
example, assessing steatosis, inflammation and fibrosis
across 8 weeks at regular intervals will allow for a
more accurate interpretation of when these histological
lesions develop. This could then be potentially used to
identify candidate biomarkers for progression of disease
from steatosis to steatohepatitis to fibrosis.
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In summary, we present a fatty liver-induced model of
hepatic fibrosis, which captures steatosis, inflammation
and fibrosis seen in NAFLD. This model holds promise
as a tool for screening for NAFLD therapeutics including
liver anti-fibrotics.
Additional files
Additional file 1: Table S1. Scheme used for histological staging of
fibrosis modified from Kleiner et al., [23].
Additional file 2: Table S2. Scheme used for histological scoring,
modified Kleiner et al., [23] and Kawasaki T et al., [24].
Additional file 3: Table S3. Body weight data of chow diet, CCL4, FFD
and FFD-CCl4. All data are expressed as mean ± SEM. The data was
statistically analyzed for significant using one-way ANOVA followed by
Dunnett’s multiple comparison post test.
Additional file 4: Table S4. Feed consumption data of chow diet,
CCL4, FFD and FFD-CCl4.
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